Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

Treatment Resistant Depression Clinical Trial

— ANU  

Official title:

A Phase I, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Treatment Resistant Depression.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02675556
• Other study ID #: 20140917
• Status: Terminated
• Phase: Phase 1
• Start date: October 31, 2017
• Est. completion date: March 26, 2019

Study information

• Verified date: March 2019
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.

Description:

This is a phase I study, with eight subjects in the pilot phase and eighty (80) subjects fulfilling all inclusion/exclusion criteria's will be randomly assigned to receive allogeneic Human Mesenchymal Stem Cell (hMSCs) or placebo in a 1:1 blinded fashion.

The 8 subjects in the pilot phase will receive a single infusion of 100 million hMSCs.

40 patients will receive a single administration of allogeneic hMSCs and another 40 patients will receive a single administration of Placebo in a 1:1 blinded fashion.

Following infusion, patients will be followed at 2, 4, 6, 8, 10 and 12 week's post-infusion to complete all safety and efficacy assessments. During these 12 weeks starting after the week 2 visit subjects will have a phone call in-between their visits. Patients will additionally be followed for up to 12 months post-infusion.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: March 26, 2019
• Est. primary completion date: March 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Provide written informed consent.

2. Subjects age equal or greater than 18 and equal or less than 75 years at the time of signing the Informed Consent Form.

3. Diagnosis of Treatment resistant depression (Failed at least two adequate trials of antidepressant monotherapy or antidepressant augmentation with an antipsychotic or lithium during the current episode)

4. Patients who are receiving a third or more treatment will only be entered if they have not responded to the current treatment.

5. Experiencing a current Major Depressive Episode (fulfilling Structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria per Structured Clinical Interview for DSM (SCID) for categorical diagnosis, and the Hamilton Depression Rating Scale for Depression (HAM-D))

6. Hamilton Depression Rating Scale 21-item score greater than 18

7. Adequacy of previous failed antidepressant trials will be defined using standard criteria by Massachusetts General Hospital (MGH) of patients with a score greater than or equal to 2.5

8. Increased inflammation ([Serum CRP] greater than 3.0 mg/L)

Exclusion Criteria:

In order to participate in this study, a patient Must Not:

1. Women who are pregnant, nursing, or of childbearing potential, while not practicing effective contraceptive methods. (Female subjects of childbearing potential must undergo a serum or urine pregnancy test at screening and within 36 hours prior to infusion.)

2. Inability to perform any of the assessments required.

3. Have clinically significant abnormal screening laboratory values, including but not limited to: hemoglobin <8 g/dl, white blood cell count <3000/mm3, platelets<80,000/mm3, INR > 1.5 not due to a reversible cause (i.e. Coumadin), aspartate transaminase, alanine transaminase, or alkaline phosphatase > 3 times upper limit of normal, total bilirubin > 1.8 mg/dl (unless due to a benign cause).

4. Active medical condition that could cause or exacerbate depressive symptoms (e.g., hypothyroidism, anemia)

5. Serious comorbid illness or any other condition (Such as bipolar, schizophrenia or schizoaffective disorder) that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.

6. Have acute suicidality

7. Prior history of a suicide attempt, within the past year.

8. Active psychotic disorder, eating disorder, or substance use disorder within 6 months of enrollment

9. Treatment with any medication that, in the opinion of the Investigator, may compromise the safety of the subject or affect the validity of the data or the study endpoints.

10. First major depressive episode after 50 years of age.

11. Have known allergies to penicillin or streptomycin.

12. Have hypersensitivity to dimethyl sulfoxide (DMSO).

13. Have a clinical history of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.

14. Have a non-pulmonary condition that limits lifespan to < 1 year.

15. Have a history of drug or alcohol abuse within the past 24 months.

16. Be serum positive for HIV, hepatitis BsAg or Viremic hepatitis C.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Treatment-Resistant
• Treatment Resistant Depression

Intervention

Drug:
• Allo-hMSCs
a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells
• Placebo
a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A

Locations

Country	Name	City	State
United States	University of Miami Miller School of Medicine	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Joshua M Hare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Reductions in serum concentrations	Reductions in serum concentrations of other inflammatory markers;	Week 12
Other	Reduction in Depressive Symptoms	Reduction in Depressive Symptoms due to change in Montgomery-Asberg Depression Rating Scale (MADRS)	Week 12
Other	Reduction in Anhedonia	Reduction in Anhedonia due to change in the Snaith Hamilton Pleasure Scale	Week 12
Other	Improvements in Cognition	Improvements in Cognition as a result of changes in Brief Assessment of Cognition for Affective Disorders (BAC-A), Performance Based Skills Assessment (UPSA-B), and Specific Level of Functioning (SLOF) scores	Week 12
Other	Improvements in Functional Capacity	Improvements in Functional Capacity as a result of changes in Brief Assessment of Cognition for Affective Disorders (BAC-A), Performance Based Skills Assessment (UPSA-B), and Specific Level of Functioning (SLOF) scores	Week 12
Other	Improvements in everyday functioning	Improvements in everyday functioning as a result of changes in Brief Assessment of Cognition for Affective Disorders (BAC-A), Performance Based Skills Assessment (UPSA-B), and Specific Level of Functioning (SLOF) scores	Week 12
Other	Mediating effects of child abuse and neglect.	Mediating effects of child abuse and neglect.	week 12
Primary	Incidence of any treatment-emergent serious adverse events (TE-SAEs)	defined as a composite of acute suicidality, and hospitalization for suicide attempts.	One month post infusion
Secondary	Reduction of Inflammation	Reduction of Inflammation: Change in serum concentrations of high sensitivity C-Reactive Protein (hs-CRP)	Week 12